X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
Europe
0
Canada
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
0
Details:
TUKYSA (tucatinib) is an oral medicine that is a tyrosine kinase inhibitor of the HER2 protein and in combination with ado-trastuzumab emtansine is being developed in patients with HER2-positive metastatic or unresectable breast cancer.
Lead Product(s): Tucatinib,Trastuzumab emtansine
Therapeutic Area: Oncology Product Name: Tukysa
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 06, 2023
Details:
TUKYSA (tucatinib) is an oral medicine that is a tyrosine kinase inhibitor of the HER2 protein and in combination with ado-trastuzumab emtansine is being developed in patients with HER2-positive metastatic or unresectable breast cancer.
Lead Product(s): Tucatinib,Kadcyla
Therapeutic Area: Oncology Product Name: Tukysa
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 16, 2023
Details:
Tukysa (tucatinib) is a TKI of HER2, inhibiting phosphorylation of HER2 and HER3, resulting in inhibition of downstream MAPK and AKT signaling and cell proliferation, and showed antitumor activity in HER2 expressing tumor cells in combination with trastuzumab.
Lead Product(s): Tucatinib,Trastuzumab
Therapeutic Area: Oncology Product Name: Tukysa
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 19, 2023
Details:
In vivo (in living organisms), TUKYSA (tucatinib) inhibited the growth of HER2-expressing tumors. The combination of TUKYSA and the anti-HER2 antibody trastuzumab showed increased anti-tumor activity in vitro and in vivo compared to either medicine alone.
Lead Product(s): Tucatinib,Trastuzumab,Oxaliplatin
Therapeutic Area: Oncology Product Name: Tuksya
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 19, 2022
Details:
At a median duration of follow-up of 20.7 months, results of MOUNTAINEER trial showed a 38.1% cORR per blinded independent central review in HER2-positive patients who were assigned to receive Tuksya (tucatinib) in combination with trastuzumab.
Lead Product(s): Tucatinib,Trastuzumab,Oxaliplatin
Therapeutic Area: Oncology Product Name: Tuksya
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 02, 2022
Details:
Pivotal HER2CLIMB trial showed that TUKYSA resulted in a robust and durable prolongation of overall survival that was consistent with results from the primary analysis for HER2-positive metastatic breast cancer patients with brain metastases.
Lead Product(s): Tucatinib,Capecitabine,Trastuzumab
Therapeutic Area: Oncology Product Name: Tukysa
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 19, 2021
Details:
Zanidatamab is a bispecific antibody, based on Zymeworks’ Azymetric™ platform. Zymeworks is developing zanidatamab in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2.
Lead Product(s): Zanidatamab,Tucatinib,Capecitabine
Therapeutic Area: Oncology Product Name: ZW25
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 19, 2021
Details:
Zanidatamab binds to HER2 across a range of expression levels and has demonstrated multiple mechanisms of action including the formation of receptor clusters, resulting in receptor internalization and downregulation that affect signal transduction .
Lead Product(s): Zanidatamab,Tucatinib,Capecitabine
Therapeutic Area: Oncology Product Name: ZW25
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 28, 2021
Details:
Pieris' option to co-develop and co-commercialize the second of 3 programs in the collaboration has been amended to provide it with a co-promotion option in the U.S, with Seagen solely responsible for the development and overall commercialization of that program.
Lead Product(s): Cinrebafusp alfa,Tucatinib
Therapeutic Area: Oncology Product Name: PRS-343
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Pieris Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 25, 2021
Details:
Patients who received TUKYSA in combination with trastuzumab and capecitabine in the pivotal trial had a 46 percent reduction in the risk of cancer progression or death compared to patients who received trastuzumab and capecitabine alone.
Lead Product(s): Tucatinib
Therapeutic Area: Oncology Product Name: Tukysa
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 12, 2021
Details:
Outcomes for TUKYSA® (tucatinib) in combination with trastuzumab and capecitabine in patients with HER2-positive metastatic breast cancer from the pivotal HER2CLIMB trial by hormone receptor (HR) status will be featured in a spotlight poster.
Lead Product(s): Tucatinib,Trastuzumab
Therapeutic Area: Oncology Product Name: Tukysa
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 08, 2020
Details:
Australian regulatory authorities have approved TUKYSA® (tucatinib) in combination with trastuzumab and capecitabine for the treatment of patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases.
Lead Product(s): Tucatinib,Trastuzumab,Capecitabine
Therapeutic Area: Oncology Product Name: Tukysa
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 12, 2020
Details:
UKYSA combination reduced risk of cancer progression in the brain or death by two-thirds, doubled response rate and reduced risk of death by nearly half compared to standard therapy alone.
Lead Product(s): Tucatinib,Trastuzumab,Capecitabine
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 29, 2020
Details:
Highlights from 12 presentations showcasing its research and development portfolio of novel targeted therapies and antibody-drug conjugate technology advances and innovation will be presented at the American Association for Cancer Research (AACR) Virtual Annual Meeting II.
Lead Product(s): Tucatinib
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 18, 2020
Details:
The approval is based on results from the pivotal trial HER2CLIMB in patients with HER2+ unresectable metastatic breast cancer who had previously received trastuzumab, pertuzumab, and ado-T-DM1.
Lead Product(s): Tucatinib,Trastuzumab,Capecitabine
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 12, 2020
Details:
First investigational therapy in a pivotal trial to include patients with metastatic HER2-positive breast cancer with active brain metastases.
Lead Product(s): Tucatinib,Trastuzumab,Capecitabine
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 31, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
